Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers

• Occurrence of solicited local and general symptoms. [ Time Frame: During the 4-day follow-up period after study vaccination. ] [ Designated as safety issue: No ]
• Occurrence of unsolicited symptoms. [ Time Frame: During the 31-days follow-up period after the study vaccination. ] [ Designated as safety issue: No ]
• Occurrence of serious adverse events (SAEs). [ Time Frame: Following vaccination. ] [ Designated as safety issue: No ]

The study will evaluate the safety and reactogenicity of PoliorixTM given as a single booster dose to Chinese children at 18-24 months of age.

Inclusion Criteria:

• A male or female toddler between, and including, 18 and 24 months of age at the time of the booster vaccination.
• Subjects who received three doses of OPV as primary vaccination in the first year of life as per Chinese recommendations.
• Subjects who the investigator believes that their parents/ guardians can and will comply with the requirements of the protocol should be enrolled in the study.
• Written informed consent obtained from the parent or guardian of the subject.
• Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

• Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
• Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccination
• Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with exception of DTP and/or Hib vaccine(s).
• Administration of immunoglobulins and/or any blood products within the three months preceding the booster vaccination, or planned administration during the study period.
• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
• Previous booster vaccination against poliomyelitis since the end of the primary vaccination series.
• History of poliomyelitis disease.
• History of seizures or progressive neurological disease.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
• Major congenital defects or serious chronic illness.

The following condition is temporary or self-limiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met:

• Current febrile illness or axillary temperature > 37.0 ºC or other moderate to severe illness within 24 hours of study vaccine administration.